KR102632745B1 - 이브루티닙을 함유하는 조성물 - Google Patents

이브루티닙을 함유하는 조성물 Download PDF

Info

Publication number
KR102632745B1
KR102632745B1 KR1020177031664A KR20177031664A KR102632745B1 KR 102632745 B1 KR102632745 B1 KR 102632745B1 KR 1020177031664 A KR1020177031664 A KR 1020177031664A KR 20177031664 A KR20177031664 A KR 20177031664A KR 102632745 B1 KR102632745 B1 KR 102632745B1
Authority
KR
South Korea
Prior art keywords
delete delete
pharmaceutical composition
sodium
ibrutinib
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177031664A
Other languages
English (en)
Korean (ko)
Other versions
KR20170134582A (ko
Inventor
딜립 골
매니쉬 쿠마르 굽타
카우츠브 탐브위카르
비누라즈 크리슈난 네어
마리스텔라 버니니
사빈 잉겔브레슈트
Original Assignee
얀센 파마슈티카 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102632745(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔브이 filed Critical 얀센 파마슈티카 엔브이
Priority to KR1020247002178A priority Critical patent/KR20240013859A/ko
Publication of KR20170134582A publication Critical patent/KR20170134582A/ko
Application granted granted Critical
Publication of KR102632745B1 publication Critical patent/KR102632745B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/22—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177031664A 2015-04-06 2016-04-06 이브루티닙을 함유하는 조성물 Active KR102632745B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247002178A KR20240013859A (ko) 2015-04-06 2016-04-06 이브루티닙을 함유하는 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06
US62/143,659 2015-04-06
PCT/US2016/026134 WO2016164404A1 (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002178A Division KR20240013859A (ko) 2015-04-06 2016-04-06 이브루티닙을 함유하는 조성물

Publications (2)

Publication Number Publication Date
KR20170134582A KR20170134582A (ko) 2017-12-06
KR102632745B1 true KR102632745B1 (ko) 2024-02-01

Family

ID=55806788

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177031664A Active KR102632745B1 (ko) 2015-04-06 2016-04-06 이브루티닙을 함유하는 조성물
KR1020247002178A Ceased KR20240013859A (ko) 2015-04-06 2016-04-06 이브루티닙을 함유하는 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247002178A Ceased KR20240013859A (ko) 2015-04-06 2016-04-06 이브루티닙을 함유하는 조성물

Country Status (29)

Country Link
US (6) US20160287594A1 (https=)
EP (3) EP3892302B8 (https=)
JP (3) JP2018513852A (https=)
KR (2) KR102632745B1 (https=)
CN (2) CN113546054A (https=)
AU (4) AU2016246669B2 (https=)
CA (1) CA2981601A1 (https=)
CL (1) CL2017002512A1 (https=)
DK (1) DK3892302T3 (https=)
EA (1) EA033992B1 (https=)
ES (1) ES2964472T3 (https=)
FI (1) FI3892302T3 (https=)
HK (1) HK1250925A1 (https=)
HR (1) HRP20231207T1 (https=)
HU (1) HUE063751T2 (https=)
IL (2) IL295941A (https=)
LT (1) LT3892302T (https=)
MA (2) MA41901A (https=)
MD (1) MD3892302T2 (https=)
MX (2) MX2017012822A (https=)
PH (1) PH12017501811A1 (https=)
PL (1) PL3892302T3 (https=)
PT (1) PT3892302T (https=)
RS (1) RS64653B1 (https=)
SG (2) SG10202103458QA (https=)
SI (1) SI3892302T1 (https=)
SM (1) SMT202300422T1 (https=)
UA (1) UA125681C2 (https=)
WO (1) WO2016164404A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
RS64653B1 (sr) 2015-04-06 2023-10-31 Janssen Pharmaceutica Nv Kompozicije koje sadrže ibrutinib
EP3523280B1 (en) 2016-10-06 2026-03-11 Janssen Pharmaceutica NV Processes and intermediates for preparing a btk inhibitor
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
KR20250016494A (ko) 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
US11576917B2 (en) 2018-01-20 2023-02-14 Natco Pharma Limited Pharmaceutical compositions comprising Ibrutinib
KR20190122561A (ko) * 2018-04-21 2019-10-30 류형준 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
EA202190045A1 (ru) 2018-06-15 2021-03-17 Янссен Фармацевтика Нв Составы/композиции, содержащие ибрутиниб
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
WO2020039264A2 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
KR102198502B1 (ko) * 2018-09-16 2021-01-05 류형준 인체의 림프순환 개선을 위한 식품 조성물
US20200171034A1 (en) * 2018-11-30 2020-06-04 Janssen Biotech, Inc. Methods Of Treating Follicular Lymphoma
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
CA3176436A1 (en) 2020-05-08 2021-11-11 Tahamtan Ahmadi Bispecific antibodies against cd3 and cd20
KR102251435B1 (ko) * 2020-11-09 2021-05-11 류형준 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물
MA63498A1 (fr) * 2021-06-10 2024-07-31 Hikma Pharmaceuticals Usa Inc. Formes posologiques orales d'ibrutinib
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
CN117064862B (zh) * 2023-04-10 2025-12-19 山东新时代药业有限公司 一种伊布替尼肠溶片及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
US20140303191A1 (en) 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
WO2015071432A1 (en) 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
US20160022942A1 (en) 2013-03-14 2016-01-28 Fisher & Paykel Healthcare Limited Catheter mount with suction port
WO2016022942A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
DE10201304A1 (de) 2002-01-15 2003-07-31 Infineon Technologies Ag Nichtflüchtige Halbleiter -Speicherzelle sowie zugehöriges Herstellungsverfahren
MX2007013467A (es) 2005-04-28 2008-01-21 Wyeth Corp Tanaproget micronizado y composiciones que contienen el mismo.
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
JO3754B1 (ar) * 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
WO2014177038A1 (en) 2013-04-28 2014-11-06 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
US9415050B2 (en) * 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
CN105452394A (zh) * 2013-08-12 2016-03-30 横滨橡胶株式会社 底漆组合物
WO2015140709A1 (en) 2014-03-19 2015-09-24 Novartis Ag Solid pharmaceutical dosage forms
MX2017001302A (es) 2014-08-01 2017-10-11 Pharmacyclics Llc Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk.
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
RS64653B1 (sr) 2015-04-06 2023-10-31 Janssen Pharmaceutica Nv Kompozicije koje sadrže ibrutinib
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140303191A1 (en) 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
US20160022942A1 (en) 2013-03-14 2016-01-28 Fisher & Paykel Healthcare Limited Catheter mount with suction port
WO2015071432A1 (en) 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
WO2016022942A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
AU2026200996A1 (en) 2026-03-05
US20260048055A1 (en) 2026-02-19
EP3280446A1 (en) 2018-02-14
MA54411A (fr) 2021-10-13
US20170252344A1 (en) 2017-09-07
IL254695B (en) 2022-10-01
US20200171036A1 (en) 2020-06-04
KR20240013859A (ko) 2024-01-30
EA201792224A1 (ru) 2018-06-29
MA41901A (fr) 2021-04-14
LT3892302T (lt) 2023-11-10
PL3892302T3 (pl) 2024-03-11
US20160287594A1 (en) 2016-10-06
WO2016164404A1 (en) 2016-10-13
EA033992B1 (ru) 2019-12-17
AU2021250925A1 (en) 2021-11-11
IL254695A0 (en) 2017-11-30
JP2018513852A (ja) 2018-05-31
JP2024026087A (ja) 2024-02-28
MX2017012822A (es) 2018-06-13
SG11201707989PA (en) 2017-10-30
CN113546054A (zh) 2021-10-26
EP3892302A1 (en) 2021-10-13
EP3892302B1 (en) 2023-09-06
HRP20231207T1 (hr) 2024-01-19
AU2024200883A1 (en) 2024-02-29
CL2017002512A1 (es) 2018-03-16
MA54411B1 (fr) 2023-11-30
EP4272835A3 (en) 2023-12-20
SG10202103458QA (en) 2021-05-28
PH12017501811A1 (en) 2018-04-23
AU2016246669B2 (en) 2021-07-15
KR20170134582A (ko) 2017-12-06
EP3892302B8 (en) 2023-10-18
CN107530293A (zh) 2018-01-02
HK1250925A1 (zh) 2019-01-18
FI3892302T3 (fi) 2023-11-03
HUE063751T2 (hu) 2024-01-28
MD3892302T2 (ro) 2024-03-31
BR112017021325A2 (pt) 2018-06-26
SI3892302T1 (sl) 2023-11-30
ES2964472T3 (es) 2024-04-08
US20230263804A1 (en) 2023-08-24
PT3892302T (pt) 2023-11-15
AU2016246669A1 (en) 2017-10-12
JP2022031690A (ja) 2022-02-22
EP4272835A2 (en) 2023-11-08
CA2981601A1 (en) 2016-10-13
UA125681C2 (uk) 2022-05-18
DK3892302T3 (da) 2023-11-13
SMT202300422T1 (it) 2024-01-10
JP7438178B2 (ja) 2024-02-26
US20220211713A1 (en) 2022-07-07
RS64653B1 (sr) 2023-10-31
IL254695B2 (en) 2023-02-01
AU2021250925B2 (en) 2023-11-16
US12364698B2 (en) 2025-07-22
IL295941A (en) 2022-10-01
MX2021015250A (es) 2022-01-24

Similar Documents

Publication Publication Date Title
KR102632745B1 (ko) 이브루티닙을 함유하는 조성물
US11642351B2 (en) Eslicarbazepine suspension
WO2018142336A1 (en) Lamotrigine suspension dosage form
TWI727983B (zh) 物理及化學穩定之口服吉維諾司他（ｇｉｖｉｎｏｓｔａｔ）懸浮液、其用途及其製備方法
US20160151295A1 (en) Oral particulate antitumor preparation
WO2022144930A1 (en) Pharmaceutical oral suspensions of riociguat
HK40061901A (en) Compositions containing ibrutinib
HK40102819A (en) Compositions containing ibrutinib
BR112017021325B1 (pt) Composições contendo ibrutinib, seu processo de preparação e uso
US20250345336A1 (en) Allopurinol oral suspension
US20210275539A1 (en) Eslicarbazepine suspension
EP4058028A1 (en) Pediatric formulations for treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171031

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210330

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230120

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231027

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240119

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240130

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240130

End annual number: 3

Start annual number: 1

PG1601 Publication of registration